Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Shares Outstanding (Diluted Average): 2009-2020

Historic Shares Outstanding (Diluted Average) for Ironwood Pharmaceuticals (IRWD) over the last 6 years, with Dec 2020 value amounting to $160.7 million.

  • Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) rose 2.08% to $161.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $161.0 million, marking a year-over-year increase of 2.08%. This contributed to the annual value of $160.7 million for FY2020, which is 2.97% up from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $160.7 million for FY2020, which was up 2.97% from $156.0 million recorded in FY2019.
  • In the past 5 years, Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) registered a high of $160.7 million during FY2020, and its lowest value of $152.6 million during FY2018.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $156.0 million (2019), whereas its average is $156.4 million.
  • Data for Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) shows a peak YoY increased of 2.97% (in 2020) over the last 5 years.
  • Yearly analysis of 3 years shows Ironwood Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $152.6 million in 2018, then increased by 2.22% to $156.0 million in 2019, then rose by 2.97% to $160.7 million in 2020.